Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Accounts Payables: 2022-2024

Historic Accounts Payables for Day One Biopharmaceuticals (DAWN) over the last 3 years, with Dec 2024 value amounting to $3.3 million.

  • Day One Biopharmaceuticals' Accounts Payables rose 91.51% to $5.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.8 million, marking a year-over-year increase of 91.51%. This contributed to the annual value of $3.3 million for FY2024, which is 26.63% up from last year.
  • As of FY2024, Day One Biopharmaceuticals' Accounts Payables stood at $3.3 million, which was up 26.63% from $2.6 million recorded in FY2023.
  • In the past 5 years, Day One Biopharmaceuticals' Accounts Payables ranged from a high of $15.9 million in FY2022 and a low of $2.6 million during FY2023.
  • Moreover, its 3-year median value for Accounts Payables was $3.3 million (2024), whereas its average is $7.3 million.
  • In the last 5 years, Day One Biopharmaceuticals' Accounts Payables slumped by 83.85% in 2023 and then climbed by 26.63% in 2024.
  • Day One Biopharmaceuticals' Accounts Payables (Yearly) stood at $15.9 million in 2022, then crashed by 83.85% to $2.6 million in 2023, then rose by 26.63% to $3.3 million in 2024.